芦可替尼治疗高龄骨髓增殖性肿瘤患者的效果  

Curative Effect Observation of Ruxolitinib for Elderly Patients with Myeloproliferative Tumors

作　　者：封国光 陈明贤[1] 韩丽丽 胡媛媛[1] 吴晨 FENG Guoguang;CHEN Mingxian;HAN Lili;HU Yuanyuan;WU Chen(Zaoyang City the First People's Hospital,Xiangyang,Hubei 441200)

机构地区：[1]枣阳市第一人民医院,湖北襄阳441200

出　　处：《智慧健康》2024年第28期107-109,共3页Smart Healthcare

摘　　要：目的 将芦可替尼用于治疗JAK2突变阳性骨髓增殖性肿瘤(MPN)患者,旨在进一步明确芦可替尼对JAK2突变阳性高龄患者的疗效。方法 选取2019年10月-2022年10月在本院住院的60名高龄MPN患者,其中30名采用常规化疗(沙利度胺+干扰素+强的松),设为传统疗法组,其余30名采用芦可替尼治疗,设为实验组。3个月后,比较两组患者脾脏大小变化、不良反应指标,从而对芦可替尼疗法在高龄骨髓增生型癌症病人中的作用进行评估。结果 实验组患者的CR/MCR值较传统疗法组显著升高,差异具有统计学意义(P<0.05)。15例患者(占总数的25.00%)有不同程度的骨髓抑制症状,其中轻度至中度(ⅠⅢ-Ⅱ级)有5例(8.33%),重度(Ⅲ-Ⅳ级)则有10例(16.67%)。11例患者(18.33%)有感染,肺部感染有6例(10.00%),显示出较高的发生率。7例患者(11.67%)有不同程度的出血现象。8例患者(13.33%)有胃肠道不适症状。2例患者(3.33%)出现了肝功能异常的现象。治疗后,两组患者的MPN-10评分、MF分级评分均比治疗前低,脾长径比治疗前短,且实验组的MPN-10评分、MF分级评分比传统疗法组更低,脾长径比传统疗法组更短,差异有统计学意义(P<0.05)。结论芦可替尼治疗高龄骨髓增殖性肿瘤患者的临床效果要优于传统疗法,有一定的临床推广价值。Objective Ruxolitinib can be used to treat patients with JAK2 mutation positive myeloproliferative tumors,the study aims to further clarify its effect for JAK2 mutation positive elderly patients.Methods The paper chose 60 elderly MCM patients in our hospital from October 2019 to October 2022.Among them,30 cases in the control group were treated with routine chemotherapy(saledamine+interferon+prednisone),and 30 cases in the experimental group with Ruxolitinib.Three months later,changes in spleen size and adverse reaction indicators based on clinical performance evaluation form(MPN-SAF-TSS)were statistically analyzed and compared between two groups,effect of Ruxolitinib therapy for elderly patients with myeloproliferative tumors was evaluated.Results Our previous research found Ruxolitinib could improve MPN-SAF-TSS symptom scores of elderly patients with myeloproliferative tumors significantly,could shrink spleen of patients effectively,thus achieve effect of"spleen shrinking".The most common side effect of the treatment was anemia and thrombocytopenia,which can be alleviated by adjusting the dosage.Conclusion Ruxolitinib can achieve good better clinical effect than traditional therapy in treatment of elderly patients with myeloproliferative tumors,which has some certain clinical promotion value.

关 键 词：疗效 芦可替尼 骨髓增殖性肿瘤 高龄 JAK抑制剂 

分 类 号：R733.3[医药卫生—肿瘤]